Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Mylan Inc    MYL   US6285301072

MYLAN INC (MYL)

60
Delayed Quote. Delayed Nasdaq - 10/30 04:14:59 pm
52.37 USD   +2.99%
1d ago MYLAN : beats Street 3Q forecasts
1d ago MYLAN : Launches Generic Viramune XR®
4d ago MYLAN : EpiPen4Schools® Program Enhances Support of National Movement to Im..
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Mylan Inc. : Mylan Launches First Generic Version of Doryx® 150 mg

04/30/2012 | 03:20pm US/Eastern

PITTSBURGH, April 30, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg, following a favorable decision by the U.S. District Court for the District of New Jersey in a patent infringement lawsuit brought by Warner Chilcott. The Court held, after trial, that Mylan's product does not infringe the subject patent. Mylan is shipping product immediately.

Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg is the generic version of Mayne Pharma's Doryx(®) 150 mg product (marketed by Warner Chilcott), and is a tetracycline-class antimicrobial.

Doxycycline Hyclate DR Tablets, 150 mg, had U.S. sales of approximately $264.1 million for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

SOURCE Mylan Inc.

Latest news on MYLAN INC
1d ago MYLAN : Results of Operations and Financial Condition (form 8-K)
1d ago MYLAN : beats Street 3Q forecasts
1d ago MYLAN : Launches Generic Viramune XR®
4d ago MYLAN : EpiPen4Schools® Program Enhances Support of National Movement to Improve..
10/22DJHealth Care Down as Biogen, Intuitive Surgical Weigh -- Health Care Roundup
10/22 MYLAN : Entry into a Material Definitive Agreement (form 8-K)
10/22 French developer of 'peanut allergy patch' makes U.S. debut
10/16 MYLAN : Other Events (form 8-K)
10/15 MYLAN : Launches Generic Combivir®
10/06 MYLAN : Launches Generic Combivir®
Dynamic quotes  
ON
| OFF